Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis

Dagmar Koethe, Andrea Giuffrida, Daniela Schreiber, Martin Hellmich, Frauke Schultze-Lutter, Stefan Ruhrmann, Joachim Klosterkotter, Daniefe Piomelli, F. Markus Leweke

Research output: Contribution to journalArticlepeer-review

119 Scopus citations


Anandamide is a bioactive lipid binding to cannabinoid receptors. A homeostatic role for anandamide has been suggested in schizophrenia. We investigated its role in initial prodromal states of psychosis. We measured the levels of anandamide and its structural analog oleoylethanolamide in cerebrospinal fluid and serum of patients in the initial prodromal state (n=27) alongside healthy volunteers (n=8D using high-performance liquid chromatograph/mass spectrometry. Cerebrospinal anandamide levels in patients were significantly elevated. Patients with lower levels showed a higher risk for transiting to psychosis earlier. This anandamidergic up-regulation in the initial prodromal course may suggest a protective role of the endocannabinoid system in early schizophrenia.

Original languageEnglish (US)
Pages (from-to)371-372
Number of pages2
JournalBritish Journal of Psychiatry
Issue number4
StatePublished - Apr 2009
Externally publishedYes

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis'. Together they form a unique fingerprint.

Cite this